Why the study?
Does therapeutic range anticoagulation with warfarin alter stroke subtype and improve clinical outcomes in patients experiencing acute ischemic stroke?
Does therapeutic range anticoagulation with warfarin alter stroke subtype and improve clinical outcomes in patients experiencing acute ischemic stroke?
Adequate anticoagulation with warfarin may prevent thrombogenesis or lead to early recanalization, resulting in better clinical outcomes, especially in patients with a history of cardioembolic stroke.
Answers are grounded in this paper and cite their sources.
May improve outcomes in prior cardioembolic stroke; hypothesis-generating and should not yet change practice.
In order to determine predictive factors of stroke recurrence during anticoagulant therapy and to estimate prognosis, we retrospectively examined clinical data of 197 consecutive patients with acute ischemic stroke. The subjects were divided into two groups, within the therapeutic range group and below therapeutic range group, based on Japanese guidelines for the management of stroke 2004. Univariate analysis revealed that cardioembolic stroke patients were less frequent in the therapeutic range group (61% vs 77%; p = 0.03), while more lacunar stroke patients were experienced (17% vs 6%; p = 0.01). In patients with past history of cardioembolic stroke, significant favorable outcomes as of Barthel index (54 vs 33; p = 0.03) and modified Rankin Scale (3 vs 4; p = 0.04) were found within the therapeutic range group. There is a possibility that adequate anticoagulation prevents thrombogenesis or lead to early recanalization, especially in patients with past history of cardioembolic stroke.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: